Omega Therapeutics CEO Mahesh Karande resigns; Kaan Certel appointed CEO and director

Omega Therapeutics, Inc.

Mahesh Karande resigned as President, CEO, and Board member effective November 14, 2024.
Kaan Certel, former Chief Business Officer, appointed President, CEO and Class I director same day.
Certel receives $520,000 base salary, 50% bonus target, and option to purchase 340,000 shares.
Karande severance includes base salary through May 25, 2025 or new employment, plus $250k transaction bonus.
Entered subleases with Flagship affiliates for ~22,350 rentable sq ft through August 31, 2026.

item 1.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mahesh Karande

President and Chief Executive Officer

Omega Therapeutics, Inc.

Effective: 2024-11-14
Successor: Kaan Certel
Filed: November 14, 2024, 6:59 PM ET

On November 14, 2024 (the " Transition Date "), Mahesh Karande tendered his resignation as President and Chief Executive Officer and as a member of the Board of Directors (the " Board ") of the Company, effective immediately.

Appointed

Kaan Certel

President and Chief Executive Officer

Omega Therapeutics, Inc.

Effective: 2024-11-14
Filed: November 14, 2024, 6:59 PM ET

On the Transition Date, the Board appointed Kaan Certel, Ph.D., the Company’s Chief Business Officer, to serve as the Company’s President and Chief Executive Officer and elected Dr. Certel to serve as a Class I director to fill the vacancy on the Board created by Mr. Karande’s resignation, in each case, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mahesh Karande resigned as President and Chief Executive Officer at Omega Therapeutics, Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On November 14, 2024 (the " Transition Date "), Mahesh Karande tendered his resignation as President and Chief Executive Officer and as a member of the Board of Directors (the " Board ") of the Company, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kaan Certel was appointed as President and Chief Executive Officer at Omega Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On the Transition Date, the Board appointed Kaan Certel, Ph.D., the Company’s Chief Business Officer, to serve as the Company’s President and Chief Executive Officer and elected Dr. Certel to serve as a Class I director to fill the vacancy on the Board created by Mr. Karande’s resignation, in each case, effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-258595

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.